The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
Open accessAbstract
Male breast cancer is a rare disease, accounting for less than 1% of all breast cancer diagnoses worldwide. Most data on male breast cancer comes from small single-institution studies, and because of the paucity of data, the optimal treatment for male breast cancer is not known. This article summarizes a multidisciplinary international meeting on male breast cancer, sponsored by the National Institutes of Health Office of Rare Diseases and the National Cancer Institute Divisions of Cancer Epidemiology and Genetics and Cancer Treatment and Diagnosis. The meeting included representatives from the fields of epidemiology, genetics, pathology and molecular biology, health services research, and clinical oncology and the advocacy community, with a comprehensive review of the data. Presentations focused on highlighting differences and similarities between breast cancer in males and females. To enhance our understanding of male breast cancer, international consortia are necessary. Therefore, the Breast International Group and North American Breast Cancer Group have joined efforts to develop an International Male Breast Cancer Program and to pool epidemiologic data, clinical information, and tumor specimens. This international collaboration will also facilitate the future planning of clinical trials that can address essential questions in the treatment of male breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Cancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
The CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104
Cancer Incidence in BRCA1 Mutation Carriers
Thompson, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1358 · Cited by 1,096
Breast carcinoma in men: A population‐based study
Giordano, S. H., Cohen, D. S., Buzdar, A. U., Perkins, G., & Hortobagyi, G. N. (2004) · Cancer · doi:10.1002/cncr.20312 · Cited by 789
Self-citationFentiman, I. S., Fourquet, A., & Hortobagyi, G. N. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68226-3 · Cited by 744
Self-citationCancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
Brose, M. S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1365 · Cited by 728
Frank, T. S., Deffenbaugh, A. M., Reid, J. E., Hulick, M., Ward, B. E., Lingenfelter, B., Gumpper, K. L., Scholl, T., Tavtigian, S. V., Pruss, D. R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1480 · Cited by 558
Giordano, S. H., Buzdar, A. U., & Hortobagyi, G. N. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-8-200210150-00013 · Cited by 490
Self-citation(2004) · The American Journal of Human Genetics · doi:10.1086/421251 · Cited by 471
A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast Cancer
Vahteristo, P., Bartkova, J., Eerola, H., Syrjäkoski, K., Ojala, S., Kilpivaara, O., Tamminen, A., Kononen, J., Aittomäki, K., Heikkilä, P., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/341943 · Cited by 467
Breast Cancer Risk Among Male BRCA1 and BRCA2 Mutation Carriers
Tai, Y. C., Domchek, S., Parmigiani, G., & Chen, S. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm203 · Cited by 430
Self-citationSasco, A. J., Lowenfels, A. B., & Jong, P. C. M. P.-D. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910530403 · Cited by 397
BRCA2 germline mutations in male breast cancer cases and breast cancer families
Couch, F. J., Farid, L. M., DeShano, M. L., Tavtigian, S. V., Calzone, K., Campeau, L., Peng, Y., Bogden, B., Chen, Q., Neuhausen, S., et al. (1996) · Nature Genetics · doi:10.1038/ng0596-123 · Cited by 363
Sørensen, H. T., Friis, S., Olsen, J. H., Thulstrup, A. M., Mellemkjær, L., Linet, M., Trichopoulos, D., Vilstrup, H., & Olsen, J. (1998) · Hepatology · doi:10.1002/hep.510280404 · Cited by 328
Goss, P. E., Reid, C., Pintilie, M., Lim, R., & Miller, N. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990201)85:3<629::aid-cncr13>3.0.co;2-v · Cited by 325
Male breast cancer: Results of the treatments and prognostic factors in 397 cases
Cutuli, B., Lacroze, M., Dilhuydy, J. M., Veiten, M., De Lafontan, B., Marchal, C., Resbeut, M., Graic, Y., Campana, F., Moncho-Bernier, V., et al. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00366-5 · Cited by 226
Self-citationPrevalence of Klinefelter's syndrome in male breast cancer patients.
Hultborn, R., Hanson, C., Köpf, I., Verbiené, I., Warnhammar, E., & WEIMARCK, A. (1998) · PubMed · Cited by 218
Occupational Exposure to Electromagnetic Fields and Breast Cancer in Men
Demers, P. A., Thomas, D. B., Rosenblatt, K. A., Jimenez, L. M., McTiernan, A., Stalsberg, H., Stemhagen, A., Thompson, W. D., Curnen, M. G. M., Satariano, W., et al. (1991) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116095 · Cited by 217
Carcinoma of the breast in males
Donegan, W. L., Redlich, P. N., Lang, P., & Gall, M. T. (1998) · Cancer · Cited by 206
Adjuvant systemic therapy for male breast carcinoma
Giordano, S. H., Perkins, G. H., Broglio, K., Garcia, S. G., Middleton, L. P., Buzdar, A. U., & Hortobagyi, G. N. (2005) · Cancer · doi:10.1002/cncr.21526 · Cited by 200
Self-citationMale breast cancer in Cowden syndrome patients with germline PTEN mutations
Fackenthal, J. D., Marsh, D. J., Richardson, A.-L., Cummings, S. A., Eng, C., Robinson, B. G., & Olopade, O. I. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.3.159 · Cited by 190
Ellis, P., Barrett-Lee, P., Johnson, L., Cameron, D., Wardley, A., O'Reilly, S., Verrill, M., Smith, I., Yarnold, J., Coleman, R., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60740-6 · Cited by 189
Self-citationJaiyesimi, I. A., Buzdar, A. U., Sahin, A. A., & Ross, M. A. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-9-771 · Cited by 185
Adjuvant Tamoxifen for male breast cancer (MBC)
Ribeiro, G., & Swindell, R. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.50 · Cited by 179
Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival
Gallagher, D. J., & Kemeny, N. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4626 · Cited by 174
Prospective Evaluation of Risk Factors for Male Breast Cancer
Brinton, L. A., Richesson, D. A., Gierach, G. L., Lacey, J. V., Park, Y., Hollenbeck, A. R., & Schatzkin, A. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn329 · Cited by 160
Molecular markers in male breast carcinoma
Rayson, D., Erlichman, C., Suman, V. J., Roche, P. C., Wold, L. E., Ingle, J. N., & Donohue, J. H. (1998) · Cancer · Cited by 150
Haraldsson, K., Loman, N., Zhang, Q., Jóhannsson, Ó. Þ., Olsson, H. L., & Borg, Å. (1998) · PubMed · Cited by 144
Male breast cancer in the veterans affairs population
Nahleh, Z. A., Srikantiah, R., Safa, M. M., Jazieh, A. R., Muhleman, A. F., & Komrokji, R. S. (2007) · Cancer · doi:10.1002/cncr.22589 · Cited by 142
Self-citationRisk Factors for Male Breast Cancer (United States)
Hsing, A. W., McLaughlin, J. K., Cocco, P., Chien, H. T. C., & Fraumeni, J. F. (1998) · Cancer Causes & Control · doi:10.1023/a:1008869003012 · Cited by 139
Risk Factors for Male Breast Cancer 2
Mabuchi, K., Bross, D., & Kessler, I. I. (1985) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/74.2.371 · Cited by 139
Status of HER-2 in male and female breast carcinoma
Bloom, K. J., Govil, H., Gattuso, P., Reddy, V., & Francescatti, D. (2001) · The American Journal of Surgery · doi:10.1016/s0002-9610(01)00733-4 · Cited by 134
Anderson, W. F., Chu, K. C., Chang, S., & Sherman, M. E. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.1128.13.7 · Cited by 127
Self-citationRibeiro, G. G. (1985) · British Journal of Cancer · doi:10.1038/bjc.1985.16 · Cited by 119
Prognosis of breast cancer in males: an analysis of 170 cases
Salvadori, B., Saccozzi, R., Manzari, A., Andreola, S. A., Conti, R. A., Cusumano, F., & Grassi, M. M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90117-1 · Cited by 111
Linkage to BRCA2 region in hereditary male breast cancer
Thorlacius, S., Ogmundsdottir, H. M., Eyfjord, J. E., Tryggvadóttír, L., Ólafsdóttir, G. H., Tulinius, H., & Jonasson, J. G. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91383-1 · Cited by 102
Male Breast Cancer Incidence Among Atomic Bomb Survivors
Ron, E., Ikeda, T., Preston, D. L., & Tokuoka, S. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji097 · Cited by 82
Weber-Chappuis, K., Bieri-Burger, S., & HURLIMANN, J. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00154-2 · Cited by 67
Leuprolide Acetate Plus Aromatase Inhibition for Male Breast Cancer
Giordano, S. H., & Hortobágyi, G. N. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2397 · Cited by 66
Self-citationA retrospective study of male breast cancer in Holland
van Geel, A. N., van Slooten, E. A., Mavrunac, M., & Hart, A. A. M. (1985) · British journal of surgery · doi:10.1002/bjs.1800720918 · Cited by 51
Curigliano, G., Colleoni, M. A., Renne, G., Mazzarol, G., Gennari, R., Peruzzotti, G., de Braud, F., Robertson, C. E., Maiorano, E., Veronesi, P., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf166 · Cited by 43
A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up
Walshe, J. M., Berman, A. W., Vatas, U., Steinberg, S. M., Anderson, W. F., Lippman, M. E., & Swain, S. M. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9363-0 · Cited by 42
Self-citationShak, S., Palmer, G. A., Baehner, F. L., Millward, C. L., Watson, D., & Sledge, G. W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.549 · Cited by 31
Cited by
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Self-citationPrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Self-citationPrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,597
Self-citationBiganzoli, L., Wildiers, H., Oakman, C., Marotti, L., Loibl, S., Kunkler, I., Reed, M., Ciatto, S., Voogd, A. C., Brain, E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70383-7 · Cited by 567
Self-citation
Metadata
- Authors
- Korde, L. A., Zujewski, J. A., Kamin, L., Giordano, S., Domchek, S., Anderson, W. F., Bartlett, J. M. S., Gelmon, K., Nahleh, Z., Bergh, J., Cutuli, B., Pruneri, G., McCaskill-Stevens, W., Gralow, J., Hortobagyi, G., & Cardoso, F.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-04-20
- Volume
- 28
- Issue
- 12
- Pages
- 2114-2122
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2141925819
- Cited by
- 487
- References
- 46
- FWCI
- 22.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.